Chronic myelogenous leukemia electrocardiogram

Revision as of 18:06, 28 December 2018 by Shyam Patel (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Chronic myelogenous leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chronic myelogenous leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic myelogenous leukemia electrocardiogram On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic myelogenous leukemia electrocardiogram

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic myelogenous leukemia electrocardiogram

CDC on Chronic myelogenous leukemia electrocardiogram

Chronic myelogenous leukemia electrocardiogram in the news

Blogs on Chronic myelogenous leukemia electrocardiogram

Directions to Hospitals Treating Chronic myelogenous leukemia

Risk calculators and risk factors for Chronic myelogenous leukemia electrocardiogram

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2] Associate Editor(s)-in-Chief: Badria Munir M.B.B.S.[3]

Overview

There are no specific EKG findings in chronic myelogenous leukemia.

Electrocardiogram

There are no specific EKG findings in chronic myelogenous leukemia. However, EKG may be necessary for patients receiving nilotinib, as this can cause cardiac toxicity and peripheral vascular disease.[1]

References

  1. Kim TD, le Coutre P, Schwarz M, Grille P, Levitin M, Fateh-Moghadam S; et al. (2012). "Clinical cardiac safety profile of nilotinib". Haematologica. 97 (6): 883–9. doi:10.3324/haematol.2011.058776. PMC 3366654. PMID 22271904.


Template:WikiDoc Sources